MX338480B - Ingenol mebutato cristalino. - Google Patents

Ingenol mebutato cristalino.

Info

Publication number
MX338480B
MX338480B MX2012011844A MX2012011844A MX338480B MX 338480 B MX338480 B MX 338480B MX 2012011844 A MX2012011844 A MX 2012011844A MX 2012011844 A MX2012011844 A MX 2012011844A MX 338480 B MX338480 B MX 338480B
Authority
MX
Mexico
Prior art keywords
ingenol mebutate
ingenol
crystalline form
relates
mebutate
Prior art date
Application number
MX2012011844A
Other languages
English (en)
Other versions
MX2012011844A (es
Inventor
Steven Martin Ogbourne
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44318125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338480(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MX2012011844A publication Critical patent/MX2012011844A/es
Publication of MX338480B publication Critical patent/MX338480B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/86—Ring systems containing bridged rings containing four rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a una nueva forma cristalina de ingenol mebutato, método de preparación del mismo, y su uso. Más específicamente, la invención se refiere a la conversión de ingenol mebutato amorfo (ingenol-3-angelato, PEPOO5) a una forma cristalina, la cual fue caracterizada por cristalografía de Rayos X (XRC) de cristal único, espectroscopia infrarroja de transformada de Fourier de reflectancia total atenuada (FTIR-ATR) y Calorimetría de Barrido Diferencial (DSC).
MX2012011844A 2010-04-16 2011-04-18 Ingenol mebutato cristalino. MX338480B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32503210P 2010-04-16 2010-04-16
PCT/IB2011/001277 WO2011128780A1 (en) 2010-04-16 2011-04-18 Crystalline ingenol mebutate

Publications (2)

Publication Number Publication Date
MX2012011844A MX2012011844A (es) 2012-11-30
MX338480B true MX338480B (es) 2016-04-19

Family

ID=44318125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011844A MX338480B (es) 2010-04-16 2011-04-18 Ingenol mebutato cristalino.

Country Status (24)

Country Link
US (2) US8653133B2 (es)
EP (1) EP2558435B1 (es)
JP (1) JP2013525300A (es)
KR (1) KR20130091647A (es)
CN (1) CN102844294A (es)
AU (1) AU2011241893B2 (es)
BR (1) BR112012026420A2 (es)
CA (1) CA2796044A1 (es)
CY (1) CY1119394T1 (es)
DK (1) DK2558435T3 (es)
ES (1) ES2633814T3 (es)
HR (1) HRP20171072T1 (es)
HU (1) HUE034138T2 (es)
IL (1) IL222265A (es)
LT (1) LT2558435T (es)
MX (1) MX338480B (es)
NZ (1) NZ603567A (es)
PL (1) PL2558435T3 (es)
PT (1) PT2558435T (es)
RS (1) RS56337B1 (es)
RU (1) RU2572618C2 (es)
SI (1) SI2558435T1 (es)
WO (1) WO2011128780A1 (es)
ZA (1) ZA201207409B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594184A (en) * 2009-02-13 2014-01-31 Leo Lab Ltd Skin treatment
HUE034138T2 (en) 2010-04-16 2018-01-29 Leo Pharma As Orthopedic crystalline ingenol mebuta
CN107011167A (zh) * 2010-07-20 2017-08-04 利奥实验室有限公司 制备巨大戟二萜醇‑3‑当归酸酯的方法
WO2012080466A2 (en) 2010-12-17 2012-06-21 Leo Pharma A/S Ingenols for treating seborrheic keratosis
WO2012176015A1 (en) * 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
AU2012327242B2 (en) * 2011-12-12 2015-10-08 Leo Laboratories Limited Gel compositions
WO2013088380A1 (en) 2011-12-12 2013-06-20 Leo Laboratories Limited Gel compositions
EP2790694A1 (en) * 2011-12-12 2014-10-22 Leo Laboratories Limited A topical composition comprising an ingenol derivative and a surfactant-cosolvent mixture
WO2013110756A1 (en) * 2012-01-26 2013-08-01 Leo Pharma A/S Ingenol mebutate in combination with cryotherapy for the treatment of actinic keratosis
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
EP2858629A1 (en) * 2012-06-08 2015-04-15 Leo Laboratories Limited A topical gel composition comprising an ingenol derivative and a solvent mixture
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222403D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222406D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
EP2931246A1 (en) * 2012-12-12 2015-10-21 Leo Laboratories Limited Gel compositions
AU2014100280B4 (en) * 2014-03-24 2015-01-15 Leo Pharma A/S A method of treating skin lesions
US9526714B2 (en) * 2014-03-24 2016-12-27 Leo Laboratories Limited Method for treating skin lesions with ingenol mebutate
CN107510651A (zh) * 2016-06-17 2017-12-26 王成 一种小分子免疫药物的纳米靶向制剂制备及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO864097A0 (en) 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
JP2007537164A (ja) * 2004-05-07 2007-12-20 マサチューセッツ・インスティテュート・オブ・テクノロジー リン酸化ｂａｃｈ１のｂｒｃａ１ｂｒｃｔドメイン認識と関係する癌治療のための方法および組成物
RU2438689C9 (ru) * 2005-06-28 2012-03-10 Амазония Фитомедикаментус ЛТДА Активная фракция экстракта млечного сока растения семейства euphorbiaceae, способ ее получения, композиция на ее основе (варианты) и способ лечения заболеваний, связанных с пролиферацией клеток (варианты)
KR20080080539A (ko) * 2005-11-14 2008-09-04 페플린 리서치 피티이 리미티드 암을 치료하기 위한 기타 제제와 병합한 안젤로일-치환된인게난의 용도
KR20080077625A (ko) * 2005-11-25 2008-08-25 페플린 리서치 피티이 리미티드 상처 치유 방법
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
BRPI0810806A2 (pt) 2007-04-30 2014-10-29 Peplin Research Pty Ltd Método para tratar uma lesão cutânea em um indivíduo
HUE034138T2 (en) 2010-04-16 2018-01-29 Leo Pharma As Orthopedic crystalline ingenol mebuta

Also Published As

Publication number Publication date
WO2011128780A1 (en) 2011-10-20
PT2558435T (pt) 2017-07-24
KR20130091647A (ko) 2013-08-19
NZ603567A (en) 2013-10-25
IL222265A (en) 2015-04-30
HUE034138T2 (en) 2018-01-29
US8653133B2 (en) 2014-02-18
US20110257262A1 (en) 2011-10-20
RS56337B1 (sr) 2017-12-29
ZA201207409B (en) 2014-06-25
DK2558435T3 (en) 2017-08-14
HRP20171072T1 (hr) 2017-10-06
CA2796044A1 (en) 2011-10-20
US20150025265A1 (en) 2015-01-22
CY1119394T1 (el) 2018-02-14
ES2633814T3 (es) 2017-09-25
CN102844294A (zh) 2012-12-26
AU2011241893B2 (en) 2014-11-06
JP2013525300A (ja) 2013-06-20
EP2558435A1 (en) 2013-02-20
LT2558435T (lt) 2017-07-25
SI2558435T1 (sl) 2017-10-30
US9440906B2 (en) 2016-09-13
BR112012026420A2 (pt) 2016-08-02
PL2558435T3 (pl) 2017-10-31
AU2011241893A1 (en) 2012-12-06
IL222265A0 (en) 2012-12-31
MX2012011844A (es) 2012-11-30
RU2572618C2 (ru) 2016-01-20
EP2558435B1 (en) 2017-06-07
RU2012148720A (ru) 2014-05-27

Similar Documents

Publication Publication Date Title
MX338480B (es) Ingenol mebutato cristalino.
MY162825A (en) Antibodies for epidermal growth factor receptor 3 (her3)
WO2011138281A3 (de) Verfahren zur herstellung von dithiin-tetracarboxy-diimiden
ZA201403880B (en) Processes fro the conversion of biomass to oxygenated organic compound, apparatus therefore and compositions produced thereby
WO2012110489A3 (en) Novel european prrsv strain
EP2557205A4 (en) PROCESS FOR PREPARING AN EPITACTIC SINGLE CRYSTAL SILICON CARBIDE SUBSTRATE AND EPITACTIC SINGLE CRYSTAL SILICON CARBIDE SUBSTRATE PRODUCED IN THIS METHOD
WO2012138801A3 (en) Lignin compositions, methods of producing the compositions, methods of using lignin compositions, and products produced thereby
MX2013011257A (es) Proceso para la preparacion de dronedarona por n-butilacion.
EA201400093A1 (ru) Кристаллические частицы, покрытые мицеллами
ZA201304962B (en) Process for the conversion of a carbohydrate-containing feedstock
PL2618663T3 (pl) Zastosowanie kompozycji do zwiększania wydajności roślin użytkowych
CR20120627A (es) Procedimiento para la preparación de diácido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico cristalino y el uso para la preparación de primovist ®
EA201200740A1 (ru) Способ пиролиза углеводов
WO2017078896A3 (en) Process for conversion of acyclic c5 compounds to cyclic c5 compounds and catalyst composition for use therein
ECSP13012365A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación,
CL2012003371A1 (es) Compuestos intermediarios de la síntesis de agomelatina; y el procedimiento de obtención de agomelatina a partir de dichos compuestos intermediarios
MX343137B (es) Dispositivo de fijacion externa.
WO2017078898A3 (en) Process for conversion of acyclic c5 compounds to cyclic c5 compounds and catalyst composition for use therein
EA201690735A1 (ru) Кристаллические формы s-ацетилглутатиона, их получение и применения в фармацевтических и нутрицевтических композициях
WO2012159981A3 (en) PROCESS FOR THE PREPARATION OF α-SUBSTITUTED KETONES AND THEIR APPLICATION IN SYNTHESIS OF PHARMACEUTICALLY ACTIVE COMPOUNDS
EA201270786A1 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
MD4477B1 (ro) Procedeu de sinteză a 3-(2-bromo-4,5-dimetoxifenil)propannitrilului şi aplicarea acestuia în sinteza ivabradinei şi a sărurilor sale de adiţie cu un acid farmaceutic acceptabil
WO2011116014A9 (en) Humanized antibodies to labyrinthin and uses thereof
MX2013010001A (es) Derivados de androstanediol como compuestos reguladores del crecimiento de las plantas.
UA68683U (en) Komarnytskyi's washer

Legal Events

Date Code Title Description
FG Grant or registration